News & Commentary

The Biden administration deserves credit for playing a key role in passing the first law in history to allow the government to negotiate lower drug prices for America’s 61 million Medicare beneficiaries. … [Read more...]

If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that one of the world’s biggest drug manufacturers was moving forward with a plan to convert the 340B program to a rebate … [Read more...]

After six months of heated battles in the states to restore access to 340B drug discounts in the contract pharmacy setting, it’s a good time to reflect on providers’ progress and setbacks.  … [Read more...]

Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight.  In fact, until the June 4th House Energy & Commerce (E&C) Oversight and Investigations Subcommittee hearing, there had not been a … [Read more...]

In last month’s column, I wrote about a reprehensible campaign by 340B opponents to tie this critically important drug discount program to the contentious issue of immigration. A dark money campaign started to pour money into red states to try to … [Read more...]

After over 30 years of working in Washington, D.C., I have become accustomed to the expression “politics ain’t beanbag.” The phrase, as the Christian Science Monitor explains, means “life is rough; get over it” to someone who receives bruising … [Read more...]

(Part Two of a Two-Part Analysis) In February, the U.S. Senate bipartisan “Group of Six” released an eagerly anticipated discussion draft bill and a bill summary/request for more information on the most highly debated issues in the 340B program. The … [Read more...]

(Part One of a Two-Part Analysis) After reviewing comments from over 250 stakeholders, meeting with various interest groups and holding regular staff meetings, the U.S. Senate bipartisan “Group of Six” have released a highly … [Read more...]

As we approach the 16-month mark since we had pivotal arguments over the 340B contract pharmacy program in two federal appellate courts and Congress continues to offer no relief, a growing number of 340B providers are turning to state legislatures … [Read more...]

Long-time 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health centers. In September, Cassidy, a long-time critic of the program, launched an inquiry into hospital use of the … [Read more...]